FeesSafety
Pluang+

JPMorgan U.S. Tech Leaders ETF (JTEK) downgraded to sell after underperformance and high risk of drawdowns

Analyst Insights
08 Nov 2026, 21:18 WIB
Seeking Alpha
View Source
Bearish
JPMorgan U.S. Tech Leaders ETF (JTEK) downgraded to sell after underperformance and high risk of drawdowns

The JPMorgan U.S. Tech Leaders ETF (JTEK) has been downgraded to a 'sell' rating due to its underperformance compared to peers and significant drawdowns. Despite a 17% drop in forward P/E since August, other tech ETFs show steeper valuation declines and better earnings growth prospects. JTEK's active strategy focuses on high growth over profitability, leading to deeper losses and slower recoveries historically. Investors may find better risk/reward profiles in alternatives like XLK and FTEC within the tech sector.

The JPMorgan U.S. Tech Leaders ETF (JTEK) is the subject, with Pluang's Technology sector market data as context. As of Nov 09, 2026 02:31 WIB, out of 150 priced US tech stocks on Pluang, 80 rose and 68 fell. Notable gainers include BTDR at USD 6.01 (+13.28%), QUBT at USD 6.33 (+12.43%), and AMD at USD 449.04 (+11.04%).

More News

NVIDIA Board launches probe into CEO Jensen Huang over foreign intelligence concerns.

NVIDIA Board launches probe into CEO Jensen Huang over foreign intelligence concerns.

NVIDIA's Board of Directors has started an independent investigation after reports that CEO Jensen Huang was targeted by a foreign intelligence operation. The inquiry, led by independent directors and external counsel, aims to ensure no national secu...

Market News
Neutral
38 minutes ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
5 hours ago
Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
5 hours ago
3 stocks with recurring revenue face challenges but offer long-term growth potential.

3 stocks with recurring revenue face challenges but offer long-term growth potential.

Three companies—Otis Worldwide, Rollins, and Republic Services—offer recurring revenue through essential services like elevator maintenance, pest control, and waste management. Despite their steady cash flows and customer loyalty, Otis and Rollins fa...

Market News
Neutral
5 hours ago
Four large crypto transfers worth $637.6M occurred in three hours, mostly Bitcoin and Tether to Bitfinex.

Four large crypto transfers worth $637.6M occurred in three hours, mostly Bitcoin and Tether to Bitfinex.

Within a three-hour window ending Nov. 6 at 4:01 p.m. ET, four major cryptocurrency transfers totaling $637.6 million took place. The largest were two Bitcoin transfers between unknown wallets, moving 3,543 BTC ($268.9M) and 2,022 BTC ($153.3M). Addi...

Market News
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App